1. Response by Murai et al to Letter Regarding Article, "Impact of Post-PCI Lipid Core Burden Index on Angiographic and Clinical Outcomes: Insights From NIRS-IVUS".
作者: Woohyeun Kim.;Hyungdon Kook.;Yonggu Lee.;Young-Hyo Lim.
来源: Circ Cardiovasc Imaging. 2025年e018586页 5. Dynamic Updating Strategies to Assess Hospital Performance of Surgical Aortic Valve Replacement.
作者: Jackie Pollack.;Wei Yang.;George J Arnaoutakis.;Michael J Kallan.;Stephen E Kimmel.
来源: Circ Cardiovasc Qual Outcomes. 2025年e011608页
Prediction models determining expected outcomes are infrequently updated (ie, static), which may reduce accuracy and misclassify hospital performance over time. Dynamic models incorporate changes over time and may improve accuracy and fairness in hospital comparisons. This study evaluated whether dynamic updating, compared with a static model, altered hospital rankings and outlier detection among surgical aortic valve replacement patients.
7. Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
作者: Samer Al Said.;Siddharth M Patel.;Robert P Giugliano.;David A Morrow.;Erica L Goodrich.;Sabina A Murphy.;Bruce Hug.;Sanobar Parkar.;Shih-Ann Chen.;Shaun G Goodman.;Boyoung Joung.;Robert G Kiss.;Wojciech Wojakowski.;Jeffrey I Weitz.;Dan Bloomfield.;Marc S Sabatine.;Christian T Ruff.
来源: Circulation. 2025年
Combining antiplatelet therapy (APT) with conventional anticoagulants increases the risk of bleeding. In the AZALEA-TIMI 71 trial (Safety and Tolerability of Abelacimab [MAA868] vs Rivaroxaban in Patients With Atrial Fibrillation), the novel factor XI inhibitor abelacimab significantly reduced the risk of bleeding compared with rivaroxaban in patients with atrial fibrillation. Whether the safety of combination antithrombotic therapy differs in the context of factor XI inhibition has not been well characterized.
8. Response by Wang et al to Letter Regarding Article, "Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis".13. Cardiac-Targeted AAV5-S100A1 Gene Therapy Protects Against Adverse Remodeling and Contractile Dysfunction in Postischemic Hearts.
作者: Dorothea Kehr.;Janek Salatzki.;Birgit Seger.;Karl Varadi.;Jennifer Birkenstock.;Philipp Schlegel.;Erhe Gao.;Walter J Koch.;Hugo Katus.;Norbert Frey.;Johannes Riffel.;Florian André.;Karsten Peppel.;Andreas Jungmann.;Martin Busch.;Helga Pfannkuche.;Julia Ritterhoff.;Patrick Most.
来源: Circ Heart Fail. 2025年e012479页
Guided by long-term safety data for AAV5 (adeno-associated virus 5) in humans, our translational study investigated whether AAV5 effectively delivers genes to healthy and achieves therapeutic efficacy in dysfunctional human-sized hearts, using a clinically applicable mode of administration and vector dosages.
15. Skeletal Muscle Quantity Versus Quality in Heart Failure: Exercise Intolerance and Outcomes in Older Patients With HFpEF Are Related to Abnormal Skeletal Muscle Metabolism Rather Than Age-Related Skeletal Muscle Loss.
作者: Sabra C Lewsey.;T Jake Samuel.;Michael Schär.;Joevin Sourdon.;Joseph R Goldenberg.;Lisa R Yanek.;Shenghan Lai.;Angela M Steinberg.;Paul A Bottomley.;Gary Gerstenblith.;Robert G Weiss.
来源: Circ Heart Fail. 2025年e012512页
Heart failure with preserved ejection fraction (HFpEF) is a systemic process with contributions from peripheral factors, including skeletal muscle (SM). Age-associated SM loss and impaired energy metabolism occur without heart failure, but the relative importance of changes in SM quantity versus metabolic quality in patients with HFpEF for exercise intolerance (EI) or outcomes has not been studied. We hypothesized that EI and subsequent clinical outcomes across the adult lifespan in patients with HFpEF are related to impaired SM energy metabolism rather than age-associated SM loss.
16. Impact of Neighborhood Factors on Exercise Capacity in Children With Hypertrophic Cardiomyopathy.
作者: Imran R Masood.;Lei Wang.;Helen M Stanley.;Jonathan J Edwards.;Humera Ahmed.;Kimberly Y Lin.;Carol A Wittlieb-Weber.;Matthew J O'Connor.;Joseph W Rossano.;Shannon O'Malley.;Stephen M Paridon.;Vicky W Tam.;Jonathan B Edelson.
来源: Circ Heart Fail. 2025年e012501页
Restricting certain patients with hypertrophic cardiomyopathy (HCM) from exercise likely has negative cardiovascular effects and has not been shown to reduce the risk of sudden cardiac death. Promoting exercise in children with HCM is complex and requires knowledge of the environmental factors that impact exercise capacity in children with HCM.
18. Implementing Precision Medicine for Dilated Cardiomyopathy: Insights From the DCM Consortium.
作者: Elizabeth Jordan.;Hanyu Ni.;Patricia Parker.;Daniel D Kinnamon.;Anjali Owens.;Brian Lowes.;Chetan Shenoy.;Cindy M Martin.;Daniel P Judge.;Daniel P Fishbein.;Douglas Stoller.;Elina Minami.;Evan P Kransdorf.;Frank Smart.;Garrie J Haas.;Gordon S Huggins.;Gregory A Ewald.;Jamie Diamond.;Jane E Wilcox.;Javier Jimenez.;Jessica Wang.;Jose Tallaj.;Mark H Drazner.;Mark Hofmeyer.;Matthew T Wheeler.;Omar Wever Pinzon.;Palak Shah.;Stephen S Gottlieb.;Stuart Katz.;Supriya Shore.;W H Wilson Tang.;Ray E Hershberger.; .
来源: Circ Genom Precis Med. 2025年e005078页 20. A Systematic Review of "Food Is Medicine" Randomized Controlled Trials for Noncommunicable Disease in the United States: A Scientific Statement From the American Heart Association.
作者: Hilary K Seligman.;Sonia Y Angell.;Seth A Berkowitz.;Mitchell S V Elkind.;Kurt Hager.;Nathalie Moise.;Hannah Posner.;Jen Muse.;Angela Odoms-Young.;Ronit Ridberg.;Andrea B Troxel.;Amy L Yaroch.;Kevin G Volpp.
来源: Circulation. 2025年
Poor diet quality is a leading risk factor for cardiometabolic disease (ie, diabetes and diseases associated with metabolism and inflammation), which is present in about half of American adults. Support has grown for incorporating the provision of healthy food as a complement to or a component of clinical care. Such "Food Is Medicine" programs provide free or subsidized healthy food directly to patients in close coordination with the health care system. In this review, we systematically examined published randomized controlled trials examining Food Is Medicine programs in the United States, categorizing them into different stages of development using the National Institutes of Health Model for Behavioral Intervention Development. This review identified a total of 14 randomized controlled trials of Food Is Medicine interventions in the United States with noncommunicable disease outcomes, more than one-third of which were early-stage smaller-scale trials (stage 1 randomized controlled trials). Broad variations in populations enrolled; intervention design, duration, and intensity; and outcomes precluded many direct comparisons between studies. Randomized controlled trial data were generally consistent with findings in the observational literature, indicating that common Food Is Medicine approaches often positively influence diet quality and food security, which are theorized to be key mediators for clinical outcomes. However, the impact on clinical outcomes was inconsistent and often failed to reach statistical significance. These observations highlight the need for larger, higher-quality Food Is Medicine studies focusing on the measurement of clinical outcomes within well-designed programs and the need for additional randomized controlled trials that more systematically map out the relationship between participation in different types of Food Is Medicine programs and health outcomes.
|